On August 8 2023, ORGANON ($NYSE:OGN) reported their earnings results for the second quarter of FY2023, ending on June 30 2023. Total revenue rose to USD 1608.0 million, a 1.5% increase compared to the same period in the prior year. Net income also increased 3.4%, reaching USD 242.0 million.
Stock opened at $22.6 and closed at $23.8, rising 9.0% from the prior closing price of 21.8. This was largely driven by an increase in digital marketing efforts and the introduction of new product lines.
In addition, ORGANON has seen a surge in demand for their products due to greater recognition from the public. The company’s CEO, Michael Dhondt, stated that these encouraging results demonstrate the strength of ORGANON’s business model and its ability to meet the changing needs of its customers. He added that ORGANON will continue to focus on delivering exceptional customer experiences and innovative products in order to maintain their competitive edge in the market. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Organon &. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Organon &. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Organon &. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Organon & are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Organon & Intrinsic Value Calculation
GoodWhale has conducted an analysis of ORGANON &‘s financials and found that its intrinsic value is around $33.5. This was determined using our proprietary Valuation Line. At the current stock price of $23.8, ORGANON & shares are undervalued by a considerable 29.0%. This presents investors with an opportunity to buy in at a discounted price and benefit from potential capital appreciation in the future. More…
Risk Rating Analysis
Star Chart Analysis
Its competitors include Creso Pharma Ltd, NGL Fine-Chem Ltd, Willow Biosciences Inc, and other similar companies.
– Creso Pharma Ltd ($ASX:CPH)
Creso Pharma Ltd is a clinical stage pharmaceutical and nutraceutical company. The company focuses on the development, registration and commercialization of cannabis and hemp derived products. Creso Pharma Ltd has a market cap of 41.48M as of 2022, a Return on Equity of -38.64%. The company has a portfolio of products in various stages of development, including a CBD-based nutraceutical, a CBD-based animal health product, and a CBD-based topical cream.
NGL Fine-Chem Ltd is a publicly traded company with a market capitalization of 8.71 billion as of 2022. The company’s return on equity is 13.3%. NGL Fine-Chem Ltd is engaged in the business of manufacturing and marketing of specialty chemicals. The company’s products are used in a variety of industries, including the automotive, aerospace, and construction industries.
– Willow Biosciences Inc ($TSX:WLLW)
Willow Biosciences Inc is a biotechnology company that develops and manufactures pharmaceutical ingredients. The company has a market capitalization of $14.85 million and a return on equity of -12.05%. Willow Biosciences is focused on providing sustainable, plant-based alternatives to traditional chemical manufacturing processes. The company’s products are used in a variety of industries, including pharmaceuticals, cosmetics, and food and beverage.
Investors responded positively to the second quarter results of ORGANON & for FY2023, with revenue increasing 1.5% and net income increasing 3.4%. The stock price saw a jump after the earnings announcement on August 8. The results demonstrate ORGANON &’s ability to generate sustainable growth despite the current economic conditions.
Furthermore, the company’s strong financial position provides further assurance to shareholders of its long-term success. Despite short-term fluctuations in the stock market, ORGANON & remains an attractive investment option for investors due to its consistent performance and strong fundamentals.